| 培美曲塞联合奥沙利铂方案和紫杉醇脂质体联合替吉奥方案二线治疗晚期胃癌的临床研究 |
| |
| 引用本文： | 张 微1,邹 玺1,沈 洁2,胡 玥1,李 烜1,胡守友1. 培美曲塞联合奥沙利铂方案和紫杉醇脂质体联合替吉奥方案二线治疗晚期胃癌的临床研究[J]. 现代肿瘤医学, 2015, 0(20): 2973-2976. DOI: 10.3969/j.issn.1672-4992.2015.20.27 |
| |
| 作者姓名： | 张 微1 邹 玺1 沈 洁2 胡 玥1 李 烜1 胡守友1 |
| |
| 作者单位： | 1.南京中医药大学附属医院,江苏省中医院，江苏 南京 210029;2.南京大学医学院附属鼓楼医院肿瘤中心，南京大学临床肿瘤学研究所，江苏 南京 210008 |
| |
| 基金项目： | 国家自然科学基金资助项目(编号:81401969) |
| |
| 摘 要： | 目的:观察培美曲塞联合奥沙利铂方案和紫杉醇脂质体联合替吉奥方案在晚期胃癌二线治疗中的近期疗效和安全性。方法:经病理组织学或细胞学确诊的60例晚期胃癌患者随机分为两组，A组28例(培美曲塞500mg/m2 iv d1，奥沙利铂85mg/m2 iv d1)，B组32例(紫杉醇脂质体135mg/m2 iv d1，替吉奥40mg/m2 bid d1~14)，21天为1周期，2周期后评价疗效及不良反应发生情况。结果:60例患者均可评价疗效，Ａ组和Ｂ组有效率分别是14.29％和18.75％(P＞0.05)，疾病控制率分别是46.43％和56.25％(P＞0.05)，中位TTP分别为5.8个月和6.2个月(P＞0.05)。化疗不良反应总体上均可耐受，A组乏力、皮疹和脱发发生率为78.57%、35.71%和25.0%(P＜0.05)，B组白细胞减少、血小板减少发生率分别为68.75%和62.50%(P＜0.05)。结论:培美曲塞联合奥沙利铂方案和紫杉醇脂质体联合替吉奥方案二线治疗晚期胃癌的近期疗效相当，不良反应可耐受，可以作为晚期胃癌的有效姑息治疗方案。
|
| 关 键 词： | 胃癌 培美曲塞 奥沙利铂 紫杉醇脂质体 替吉奥 化学治疗 |
Clinical study of pemetrexed combined with oxaliplatin and paclitaxel liposome combined with S -1 second -line treatment of advanced gastric cancer |
| |
| Zhang Wei1,Zou Xi1,Shen Jie2,Hu Yue1,Li Xuan1,Hu Shouyou1. Clinical study of pemetrexed combined with oxaliplatin and paclitaxel liposome combined with S -1 second -line treatment of advanced gastric cancer[J]. Journal of Modern Oncology, 2015, 0(20): 2973-2976. DOI: 10.3969/j.issn.1672-4992.2015.20.27 |
| |
| Authors: | Zhang Wei1 Zou Xi1 Shen Jie2 Hu Yue1 Li Xuan1 Hu Shouyou1 |
| |
| Affiliation: | 1.Jiangsu Province Hospital of Traditinal Chinese Medicine,Jiangsu Nanjing 210029,China;2.The Comprehensive Cancer Center of Drum-Tower Hospital,Medical School of Nanjing University ＆ Clinical Cancer Institute of Nanjing University,Jiangsu Nanjing 210008,China. |
| |
| Abstract: | Objective:To evaluate the efficacy and safety of pemetrexed combined with oxaliplatin and paclitaxel liposome combined with S-1 in the second-line chemotherapy of advanced gastric cancer.Methods:A total of 60 patients with advanced gastric cancer were randomly divided into two groups.There were 28 patients in group A(pemetrexed 500mg/m2 iv d1,oxaliplatin 85mg/m2 iv d1)and 32 patients in group B (paclitaxel liposome 135mg/m2 iv d1,S-1 40mg/m2 bid d1~14).Both two regimens were 21 days as a cycle，and a total of 2 cycles were applied.The efficacy and side effects were evaluated after 2 cycles.Results:Patients in group A received 4 PR,9 SD,15 PD to contrast group B 6 PR,12 SD,14 PD,in both two groups had no CR case.No statistical difference was found between the two groups in regard to response rate(14.29% vs 18.75%),disease control rate(46.43% vs 56.25%) and TTP(5.8 months vs 6.2 months).The group A had higher frequency of hypodynamia,skin eruption and alopecia (P＜0.05),while the group B had higher frequency of leukocyte and thrombocytopenia(P＜0.05).Conclusion:Pemetrexed combined with oxaliplatin and paclitaxel liposome combined with S-1 are effective and tolerated,can be used as two palliative treatment for advanced gastric cancer. |
| |
| Keywords: | advanced gastric cancer pemetrexed oxaliplatin paclitaxel liposome S-1 chemotherapy |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
